See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Liberation Day
Tariffs
Donald Trump
Trade War
Natural Disasters
Baseball
Senate
Republican Party
Social Media
Artificial Intelligence
Democratic Party
Tennis
Published • loading... • Updated

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Summary by Hastings Tribune
- Prime Editing has potential to be best-in-class approach for AATD -

4 Articles

All
Left
Center
3
Right
STATSTAT
Center

Prime and Beam, born of same lab, pursuing rival gene-editing treatments

The gene-editing field may have yet another legal squabble on its hands — this time between two companies created by the same star biotech researcher, in a dispute that gets at the core of some of the challenges facing the field.  On Tuesday, Prime Medicine announced it was developing a gene-editing treatment for a debilitating lung and liver disorder called alpha-1-antitrypsin deficiency. On the surface, it’s an unsurprising move. AATD may affe…

·Boston, United States
Read Full Article
biopharmadive.combiopharmadive.com
Center

Prime sets sights on liver, lung disease as next target for its gene editing tech

The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.

Read Full Article
Hastings TribuneHastings Tribune
Center

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

- Prime Editing has potential to be best-in-class approach for AATD -

Read Full Article
Pharmaceutical Business reviewPharmaceutical Business review

FDA grants orphan drug status for Korro Bio's AATD therapy

This investigational medicine is stated to be the “first” ribonucleic acid (RNA) editing development candidate from the company’s Oligonucleotide Promoted Editing of RNA (OPERA) platform. Korro Bio chief The post FDA grants orphan drug status for Korro Bio’s AATD therapy appeared first on Pharmaceutical Business review.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaceutical Business review broke the news in on Monday, March 17, 2025.
Sources are mostly out of (0)

Similar News Topics

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal